Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Zinc Sulfate
Overview
What is Zinc Sulfate?
Concentrated Zinc Sulfate Injection, USP is a sterile, non-pyrogenic solution intended for use as an additive to solutions for Total Parenteral Nutrition (TPN). Each mL contains Zinc Sulfate (Anhydrous) 12.32 mg, Water for Injection q.s. pH adjusted with Sulfuric Acid. It contains no preservatives. Discard unused portion. It delivers elemental zinc 5 mg per mL.
What does Zinc Sulfate look like?
What are the available doses of Zinc Sulfate?
Sorry No records found.
What should I talk to my health care provider before I take Zinc Sulfate?
Sorry No records found
How should I use Zinc Sulfate?
Concentrated Zinc Sulfate Injection, USP is indicated for use as a supplement to intravenous solutions given for TPN. Administration helps to maintain plasma levels and to prevent depletion of endogenous stores.
Concentrated Zinc Sulfate Injection, USP provides 5 mg zinc/mL. For metabolically stable adults receiving TPN, the suggested intravenous dosage is 2.5 to 4 mg zinc/day. An additional 2 mg zinc/day is suggested for acute catabolic states. For the stable adult with fluid loss from the small bowel, an additional 12.2 mg zinc/liter of small bowel fluid lost, or an additional 17.1 mg zinc/kg of stool or ileostomy output is recommended. Frequent monitoring of zinc blood levels is suggested for patients receiving more than the usual maintenance dosage level of zinc.
For full term infants and children up to 5 years of age, 100 mcg zinc/kg/day is recommended. For premature infants (birth weight less than 1500 g) up to 3 kg in body weight, 300 mcg zinc/kg/day is suggested.
Aseptic addition of Concentrated Zinc Sulfate Injection, USP to the TPN solution under a laminar flow hood is recommended. Zinc is physically compatible with the electrolytes and vitamins usually present in the amino acid/dextrose solution used for TPN.
Parenteral drug products should be inspected visually for particulate matter and discoloration, whenever solution and container permit.
What interacts with Zinc Sulfate?
Sorry No Records found
What are the warnings of Zinc Sulfate?
Sorry No Records found
What are the precautions of Zinc Sulfate?
Sorry No Records found
What are the side effects of Zinc Sulfate?
Sorry No records found
What should I look out for while using Zinc Sulfate?
Concentrated Zinc Sulfate Injection, USP should not be given undiluted by direct injection into a peripheral vein because of the likelihood of infusion phlebitis and the potential to increase renal loss of zinc from a bolus injection.
This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
What might happen if I take too much Zinc Sulfate?
Symptoms of zinc overdosage resulting from oral ingestion of zinc sulfate in large amounts (30 and 44 grams, respectively) have resulted in death. Symptoms included nausea, vomiting, dehydration, electrolyte imbalances, dizziness, abdominal pain, lethargy and incoordination. Single intravenous doses of 1 to 2 mg zinc/kg body weight have been given to adult leukemic patients without toxic manifestations. Normal plasma levels for zinc vary from approximately 88 to 112 mcg/100 mL. Plasma levels sufficient to produce symptoms of toxic manifestations in humans are not known. Calcium supplements may confer a protective effect against zinc toxicity.
How should I store and handle Zinc Sulfate?
Concentrated Zinc Sulfate Injection, USP, 5 mg zinc/mLNDC 0517-8105-25 5 mL Vials Packed in a box of 25Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)(See USP Controlled Room Temperature).AMERICANREGENT, INC.SHIRLEY, NY 11967IN8105Rev. 1/09MG #14229Concentrated Zinc Sulfate Injection, USP, 5 mg zinc/mLNDC 0517-8105-25 5 mL Vials Packed in a box of 25Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)(See USP Controlled Room Temperature).AMERICANREGENT, INC.SHIRLEY, NY 11967IN8105Rev. 1/09MG #14229Concentrated Zinc Sulfate Injection, USP, 5 mg zinc/mLNDC 0517-8105-25 5 mL Vials Packed in a box of 25Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)(See USP Controlled Room Temperature).AMERICANREGENT, INC.SHIRLEY, NY 11967IN8105Rev. 1/09MG #14229Concentrated Zinc Sulfate Injection, USP, 5 mg zinc/mLNDC 0517-8105-25 5 mL Vials Packed in a box of 25Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)(See USP Controlled Room Temperature).AMERICANREGENT, INC.SHIRLEY, NY 11967IN8105Rev. 1/09MG #14229Concentrated Zinc Sulfate Injection, USP, 5 mg zinc/mLNDC 0517-8105-25 5 mL Vials Packed in a box of 25Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)(See USP Controlled Room Temperature).AMERICANREGENT, INC.SHIRLEY, NY 11967IN8105Rev. 1/09MG #14229Concentrated Zinc Sulfate Injection, USP, 5 mg zinc/mLNDC 0517-8105-25 5 mL Vials Packed in a box of 25Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)(See USP Controlled Room Temperature).AMERICANREGENT, INC.SHIRLEY, NY 11967IN8105Rev. 1/09MG #14229Concentrated Zinc Sulfate Injection, USP, 5 mg zinc/mLNDC 0517-8105-25 5 mL Vials Packed in a box of 25Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)(See USP Controlled Room Temperature).AMERICANREGENT, INC.SHIRLEY, NY 11967IN8105Rev. 1/09MG #14229Concentrated Zinc Sulfate Injection, USP, 5 mg zinc/mLNDC 0517-8105-25 5 mL Vials Packed in a box of 25Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F)(See USP Controlled Room Temperature).AMERICANREGENT, INC.SHIRLEY, NY 11967IN8105Rev. 1/09MG #14229
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Zinc has been identified as a cofactor for over 70 different enzymes, including alkaline phosphatase, lactic dehydrogenase and both RNA and DNA polymerase. Zinc facilitates wound healing, helps maintain normal growth rates, normal skin hydration and the senses of taste and smell.
Providing zinc during TPN prevents development of the following deficiency symptoms: Parakeratosis, hypogeusia, anorexia, dysosmia, geophagia, hypogonadism, growth retardation and hepatosplenomegaly. At plasma levels below 20 mcg zinc/100 mL, dermatitis followed by alopecia has been reported for TPN patients.
Non-Clinical Toxicology
Concentrated Zinc Sulfate Injection, USP should not be given undiluted by direct injection into a peripheral vein because of the likelihood of infusion phlebitis and the potential to increase renal loss of zinc from a bolus injection.This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.
Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.
Other sympathomimetic aerosol bronchodilators or epinephrine should not be used concomitantly with albuterol.
Albuterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of albuterol on the vascular system may be potentiated.
Beta-receptor blocking agents and albuterol inhibit the effect of each other.
Administration of zinc in the absence of copper may cause a decrease in serum copper levels. Periodic determination of serum copper as well as zinc are suggested as a guideline for subsequent zinc administration. Zinc is eliminated via the intestine and kidneys. The possibility of retention should be considered in patients with malfunctioning excretory routes.
The amount of zinc present in Concentrated Zinc Sulfate Injection, USP is very small, symptoms of toxicity from zinc are considered unlikely to occur.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).